Accent Therapeutics, Inc.

At Accent Therapeutics, we are proud to celebrate not only International Women's Day on March 8th but also the entire month of March, which is dedicated to honoring Women's History Month. With 57% women on our team, we recognize the incredible contributions of every woman at Accent who is helping us shape the future of science, innovation, and leadership. From breakthroughs in research to everyday moments of collaboration and inspiration, the women at Accent are truly making history.?We are committed to fostering an environment where women thrive, lead, and make a positive impact, both within our company and beyond.?Today and every day, we celebrate you! ???? #InternationalWomensDay #WomensHistoryMonth #WomenInLeadership #WomenInScience?

Join our team!?We're looking for a Director of Clinical Operations and a Medical Director to lead clinical trial design and execution for our exciting small molecule precision oncology programs.?If you're a passionate leader, ready to shape the future of clinical operations, we want to hear from you! #ClinOps #MedicalDirector #Oncology #PatientFocus https://lnkd.in/gDnZXddy

Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition https://lnkd.in/gsf7PMr3

Our portfolio company Accent Therapeutics, Inc. has dosed the first patient with the first-in-class oral DHX9 inhibitor ATX-559 in its Phase 1/2 trial. To learn more about Accent's discovery and development of DHX9 inhibitor, take a look at a recent publication from Accent Therapeutics, Inc. here: https://lnkd.in/g8VZuz6u Naveen Krishnan David T. Paik Mirae Asset Capital Life Science Mirae Asset Capital #DHX9 #PrecisionOncology #AccentTherapeutics #MSI #dMMR

We express our deep and enduring gratitude to Robert Copeland for his leadership and foundational contributions to Accent! #oncology #cancerresearch #drugdevelopment

Please join us in congratulating Serena Silver, Ph.D. in her appointment as Accent’s CSO, effective January 1, 2025! Dr. Silver joined Accent in September 2022 as Vice President of Biology, bringing a breadth of experience across target discovery, drug discovery, and translational research. We are grateful for her ongoing leadership as we enter clinical development. #oncology #cancerresearch #drugdevelopment

?? NEWS: The first patient has been dosed in Accent’s Phase 1/2 trial of ATX-559, our first-in-class oral DHX9 inhibitor! Learn more: https://bit.ly/41nQrkR #cancerresearch #drugdevelopment #DHX9 #clinicaltrial #breastcancer #colorectalcancer

If attending the RNA-Targeted Drug Discovery & Development Summit in Boston this week, be sure to prioritize Dr. Kenny Duncan's seminar on Wednesday, December 11th. He will be presenting Accent's development of DHX9 inhibitors for MSI-high and BRCA-deficient cancers as well as discovery of allosteric inhibitors of XRN1. #AccentTherapeutics #DrugDiscovery #DHX9 #XRN1 #Kenneth Duncan https://lnkd.in/ex7kz3zS

Accent is thrilled to announce the publication of the research validating the RNA and DNA/RNA hybrid helicase DHX9 as a target for microsatellite-instable high (MSI-H) tumors with defective mismatch repair (dMMR) in the journal Cancer Research, as well as the identification of the tool compound, ATX968.??This groundbreaking study is the first report detailing the in vivo efficacy of a DHX9 inhibitor, providing proof of concept for inhibition of DHX9 enzymatic activity as a potential therapeutic in select cancers.? ? This work was made possible through the hard work and collaborative efforts of our dedicated research team and CRO partners. ? We are immensely proud of this achievement and look forward to the positive impact it will have on the scientific community and future therapeutic developments. ? #DHX9 #CancerResearch #ChemicalBiology #AccentTherapeutics ? Read the full paper here: https://lnkd.in/ewg8Uk9x ?

Accent is well represented at the AACR Special Conference in Cancer Research: RNAs as Drivers, Targets, and Therapeutics in Cancer, held in Bellevue, Washington! Serena Silver, Head of Biology, will present data on Accent’s lead program,, the RNA helicase DHX9. Ann Boriack-Sjodin, Head of Molecular Discovery, will share insights on our early-stage efforts on the RNA exoribonuclease XRN1. Dr. Howard Chang of Stanford University, and co-founder of Accent, is a key conference organizer. Thank you to our incredible team for representing Accent and exemplifying our core values of Patient Focus, Contagious Enthusiasm, and Rigor^2! #CancerResearch #AACR #RNA #DHX9 #XRN1 #AccentTherapeutics https://lnkd.in/giwqY-qd